Clinical Trial Update: A Pharmacokinetic Study of Once Daily Efavirenz 400 mg Versus 600 mg in Thai HIV-1 Infected Subjects [Phase 2]

View source ↗

Summary

Phase 2 pharmacokinetic study comparing once-daily efavirenz 400 mg vs 600 mg in Thai HIV-1 infected subjects to evaluate PK differences.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• EFAVIRENZ (efavirenz)

Snippet

Sponsor: The HIV Netherlands Australia Thailand Research Collaboration | Conditions: HIV Infections | Phase 2 | Status: COMPLETED